Shots:

• The non-IND/CTA study evaluates KB295 in patients with UC. The study evaluates other exploratory assessments including changes in microbiome composition- SCFA levels & biomarkers of inflammation
• The clinical study met its 1EP i.e.- patients achieved a reduction in 3 biomarkers includes a reduction in median FCP levels (69%)- patients identified as responders (74%)- reduction in median Fecal lactoferrin & FimH (69% & 93%). The therapy was well tolerated
• The pre-clinical data from ex-vivo studies showed community-wide changes & modulation of multiple remission-associated taxa- production of SCFA increases. The company plan to start P-II study of KB295- based on pre/clinical data in H1’22

Ref: Globe Newswire | Image: Businesswire